| Antimicrobial peptides for combating drug-resistant bacterial infections J Xuan, W Feng, J Wang, R Wang, B Zhang, L Bo, ZS Chen, H Yang, ... Drug Resistance Updates 68, 100954, 2023 | 126 | 2023 |
| Putrescine protects hulless barley from damage due to UV-B stress via H2S- and H2O2-mediated signaling pathways Q Li, Z Wang, Y Zhao, X Zhang, S Zhang, L Bo, Y Wang, Y Ding, L An Plant cell reports 35, 1155-1168, 2016 | 49 | 2016 |
| Drug resistance: from bacteria to cancer H Patel, ZX Wu, Y Chen, L Bo, ZS Chen Molecular Biomedicine 2, 1-19, 2021 | 24 | 2021 |
| Establishment and characterization of an irinotecan-resistant human colon cancer cell line ZX Wu, Y Yang, L Zeng, H Patel, L Bo, L Lin, ZS Chen Frontiers in oncology 10, 624954, 2021 | 19 | 2021 |
| The battlefield of chemotherapy in pediatric cancers L Bo, Y Wang, Y Li, JND Wurpel, Z Huang, ZS Chen Cancers 15 (7), 1963, 2023 | 10 | 2023 |
| Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer Y Xie, Q Lu, JQ Wang, L Bo, CR Ashby Jr, ZS Chen Drugs Today (Barc) 58 (8), 389-398, 2022 | 3 | 2022 |
| Nanotechnology-based delivery systems to overcome drug resistance in cancer H Patel, J Li, L Bo, R Mehta, CR Ashby Jr, S Wang, W Cai, ZS Chen Medical Review 4 (1), 5-30, 2024 | 2 | 2024 |
| Combating antimicrobial resistance: the silent war L Bo, H Sun, YD Li, J Zhu, JND Wurpel, H Lin, ZS Chen Frontiers in Pharmacology 15, 1347750, 2024 | 2 | 2024 |
| Therapeutic evolution in HR+/HER2-breast cancer: from targeted therapy to endocrine therapy LQ Cao, H Sun, Y Xie, H Patel, L Bo, H Lin, ZS Chen Frontiers in Pharmacology 15, 1340764, 2024 | 2 | 2024 |
| The roles of exosomal microRNAs in diffuse large B-cell lymphoma: Diagnosis, prognosis, clinical application, and biomolecular mechanisms S Yazdanparast, Z Huang, S Keramat, M Izadirad, YD Li, L Bo, ... Frontiers in Oncology 12, 904637, 2022 | 2 | 2022 |
| The Batlefield of Chemotherapy in Pediatric Cancers. Cancers 2023, 15, 1963. htps L Bo, Y Wang, Y Li, JND Wurpel, Z Huang, ZS Chen doi. org/10.3390/cancers15071963 Academic Editor: David Wong Received 10, 2023 | | 2023 |
| The Repotrectinib Z Li, L Bo, S Talukder, FF Ping, ZS Chen DRUGS OF THE FUTURE 47 (9), 661-674, 2022 | | 2022 |
| Erfonrilimab J Qin, Z Shi, QX Teng, L Bo, C Han, ZS Chen DRUGS OF THE FUTURE 47 (6), 419-427, 2022 | | 2022 |
| Repotrectinib. ALK/ROS1/TRK inhibitor, Treatment of solid tumors Z Li, L Bo, S Talukder, FF Ping, ZS Chen Drugs of the Future 47 (9), 2022 | | 2022 |
| Erfonrilimab. Bispecific anti-PD-L1/CTLA-4 antibody, Cancer immunotherapy J Qin, Z Shi, QX Teng, L Bo, C Han, ZS Chen Drugs of the Future 47 (6), 2022 | | 2022 |
| Eganelisib. Phosphatidylinositol 3-kinase gamma (PI3Kgamma) inhibitor, Treatment of triple-negative breast cancer L Bo, YK Zhang, SE Reznik, ZS Chen Drugs of the Future 46 (12), 2021 | | 2021 |
